CD4 and cancer: Consistent with identification of the CD4-LCK-MEC2C axis, CD4 was identified as a key contributor to the PD1/PD-L1 immunotherapy efficacy, showing a critical role of CD4-mediated pathway in antagonizing cancer [40].